BRAF+ melanoma: BRAF/MEK, PD-1 inhibition best for OS

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • BRAF/MEK and PD-1 inhibition significantly improved OS in this population.
Why this matters
  • The favorable safety profile of PD-1 inhibitors lends support to its use as a first-line option when rapid response is not a priority.
Study design
  • Meta-analysis that included 16 articles reportin...